What does the FDA's expanded approval of Tzield mean for newly diagnosed pediatric type 1 diabetes?

In June 2026, the FDA granted accelerated approval for Tzield (teplizumab) to delay insulin decline in children aged 8–17 newly diagnosed with Stage 3 type 1 diabetes. This marks the first authorization for this use, extending Tzield’s role beyond pre‑symptomatic patients and reflecting FDA’s openness to surrogate biomarkers in chronic disease approvals.